1. ScrMMP-1 Supplementary Fig. 1, Ganguly et al. 0 25 50 75 100 ScrMMP-3 ScrMMP-3MT1-MMP 100 m Relative Invasion 0 25 50 75 100 Scr MMP-1 100 m abc Scr Scr MT1-MMP 50 75 0 25 100 Relative Invasion MT1-MMP Actin 600 200 Actin MMP-3 siRNA: Scr MMP-3 200 400 Actin MMP-1 200 300 siRNA: Scr MMP-1 siRNA: Scr MT1-MMP

2. Supplementary Fig. 2, Ganguly et al. Relative MMP-1 expression (MMP-1/ -Actin) 0 0.25 50 75 100 STI571: - + Actin MMP-1 200 300

3. GST-CrkGST-STAT3GST GST-STAT3 GST-Crk Abl PP Arg PP Abl PP Arg PP Abl PP IP: 182 26 115 82 64 49 37 GST Supplementary Fig. 3, Ganguly et al. Autophosphorylated c-Abl/Arg GST:

4. Supplementary Fig. 4, Ganguly et al. Primers: Abl Arg siRNA: Scr Abl Arg Scr Abl Arg Scr Abl Arg Scr Abl Arg Percent of: 100 44 76 100 35 103 100 121 14 100 166 18 Scrambled Actin GFP GFP-MMP-1 Abl/Arg Cell Line:

5. 3 H-Thymidine Incorporation (CPM X10 4 ) 0 2 4 6 8 10 12 14 Supplementary Fig. 5, Ganguly et al. Scr STAT3 a 0 10 20 30 40 siRNA: Scr Arg Scr Arg pcDNA STAT3C b Cleavage product STI571: - + - + pcDNA STAT3C 115 82 Percent of Untreated: 100 437 100 270 c 49 -actin blot 3 H-Thymidine Incorporation (CPM X10 4 ) Relative PARP Cleavage (PARP/ -actin) STI571: - + - + PARP blot 0 100 200 300 400 500 pcDNA STAT3C

6. Supplementary Fig. 6, Ganguly et al. PARP blots STI571: - + - + - + -actin blot 115 82 37 Treatment/Starvation Time: 48h 96h Cleavage product GAPDH blot 37

7. Supplementary Fig. 7, Ganguly et al.